Tenapanor + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Irritable Bowel Syndrome With Constipation (IBS-C)
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Trial Timeline
Jul 24, 2024 → Jun 1, 2026
NCT ID
NCT06553547About Tenapanor + Placebo
Tenapanor + Placebo is a phase 2 stage product being developed by Ardelyx for Irritable Bowel Syndrome With Constipation (IBS-C). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06553547. Target conditions include Irritable Bowel Syndrome With Constipation (IBS-C).
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06460038 | Phase 2 | Recruiting |
| NCT06553547 | Phase 2 | Recruiting |
| NCT02675998 | Phase 3 | Completed |
| NCT02686138 | Phase 3 | Completed |
| NCT02621892 | Phase 3 | Completed |
Competing Products
20 competing products in Irritable Bowel Syndrome With Constipation (IBS-C)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| linaclotide + placebo | Astellas Pharma | Phase 2 | 52 |
| YM060 + Placebo | Astellas Pharma | Phase 3 | 77 |
| Ramosetron + Placebo | Astellas Pharma | Approved | 85 |
| Ramosetron + Placebo | Astellas Pharma | Approved | 85 |
| YM060 | Astellas Pharma | Phase 3 | 77 |
| YM060 + placebo | Astellas Pharma | Phase 2 | 52 |
| YM060 | Astellas Pharma | Phase 3 | 77 |
| linaclotide + Placebo | Astellas Pharma | Phase 3 | 77 |
| Ramosetron | Astellas Pharma | Pre-clinical | 23 |
| YM060 | Astellas Pharma | Phase 2 | 52 |
| ONO-2952 + Placebo comparator | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-2952 + ONO-2952 Matching Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| duloxetine | Eli Lilly | Approved | 85 |
| Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers) | AbbVie | Phase 3 | 77 |
| 25mg Eluxadoline + 100mg Eluxadoline | AbbVie | Phase 3 | 77 |
| Eluxadoline + Placebo | AbbVie | Phase 2 | 52 |
| Placebo + Linaclotide | AstraZeneca | Phase 3 | 77 |
| Tegaserod | Novartis | Pre-clinical | 23 |
| DNK333 | Novartis | Phase 2 | 52 |
| SMS995 + Placebo | Novartis | Phase 1 | 33 |